CONAGRA BRANDS INC. (CAG) stock intrinsic value fair value estimate & owner earnings analysis

Conagra Brands makes packaged food sold mainly in US supermarkets and to restaurants and institutions. Its brands include Birds Eye, Banquet, Marie Callender's, Healthy Choice, Slim Jim, Duncan Hines, Reddi-wip, Orville Redenbacher's, Hunt's and PAM. Our estimates of what the shares are worth are $4.16 (bear), $14.84 (base) and $29.97 (bull). Because the company carries about $7.1 billion of net debt against a business worth roughly $9 to $21 billion, small changes in the business value move the value of the shares a lot, which is why the range is wide. What has happened. Fiscal 2026 (ended May 31, 2026, a 53-week year) net sales were $11.28 billion, down 2.9%. More than $500 million of prior-year sales came from Chef Boyardee and frozen fish, both sold in the first quarter of fiscal 2026 for about $649 million, and the extra week added about 1.8%, so underlying sales were roughly flat. Volumes were weaker (Grocery & Snacks down 2.4%, Foodservice down 2.2%, International down 4.2%), with price increases covering part of that. Profit fell more sharply: segment operating profit dropped to about $1.62 billion from $1.94 billion, with Grocery & Snacks down 13.0% to $885 million and Refrigerated & Frozen down 25.5% to $486 million, which the company attributes to input cost inflation and lower operating leverage. The reported net loss of $1.92 billion comes mainly from non-cash write-downs of $2.38 billion of goodwill and $547 million of brand values in Refrigerated & Frozen. We do not treat those write-downs as a cash cost, but the company's own test lowered the value of those businesses, and we read that as confirmation that profits are under real pressure. Operating cash flow held up at $1.40 billion. How we measured earnings. We start from operating cash flow and remove swings in working capital (inventories, receivables, payables and, in the last three years, litigation accruals and payments, which we treat as timing), then subtract stock compensation and the part of capital spending needed to keep the plants running. Because the company's income-tax line mixes real tax payments with non-cash deferred-tax items (fiscal 2025 included a $253.5 million non-cash tax benefit), we leave it in earnings rather than treating it as working capital. Then we add back the interest the company pays, value the business before its lenders, and subtract the debt. Earnings after interest per share were $1.89, $2.51, $2.90, $2.21 and $1.73 for fiscal 2022 through 2026. Adding back interest gives business cash flow per share of $2.70, $3.38, $3.83, $3.10 and $2.51. We measured the level from fiscal 2022 onward (the five years after pandemic-boosted demand in fiscal 2020 and 2021), where the median is $3.10 per share. Where we start. Business cash flow fell 19% in fiscal 2026, and the base case starts fiscal 2027 at $2.19 per share, a further decline of about 13%. We do not assume a return to the $3.10 median. The dated reasons for going lower are in the annual report: the 53rd week will not repeat (worth about $0.05 per share), and the company plans fiscal 2027 capital spending of about $550 million, up from $423 million (about $0.27 per share). The report also expects continued elevated input cost inflation in fiscal 2027, with price increases and the volume losses that come with them. Nothing in the filings shows a contracted or dated reason for profits to bounce back, so we leave a rebound out of the base case. Base case: $14.84 per share. From $2.19, business cash flow declines 1.5% a year and we credit no growth. No contracts, backlog or proven repeatable expansion put growth in the bag; volumes are falling. What supports the earnings continuing at all is the portfolio of long-established brands, which generated roughly $1.2 billion or more of cash before interest in each of the last seven years, including through the 2022 to 2024 inflation squeeze. The business is worth about $14.0 billion ($29.20 per share). It owes about $6.9 billion, so shareholders' claim is about $7.1 billion, or $14.84 per share. Bear case: $4.16 per share. Another year like the last two (segment profit fell 13% and 25.5% in fiscal 2026) takes business cash flow to $1.75 per share, about $840 million, and it then declines 3% a year as volumes keep slipping. The business is worth about $9.3 billion. The debt, including roughly $200 million of extra cost from refinancing about $3.5 billion of notes falling due by late 2028 at higher rates, is about $7.3 billion, leaving about $2.0 billion for shareholders. Cash flow of about $840 million still covers the $374 million of annual interest about 2.2 times, so the debt remains serviceable in this case. Bull case: $29.97 per share. The company's own levers execute: its Project Catalyst productivity program (about $40 million of fiscal 2027 spending), and continued pricing power shown by Foodservice price and mix up 3.6%. Business cash flow rebuilds to $2.40, $2.65 and $2.90 per share over three years, still below the five-year median and the $3.83 earned in fiscal 2024, then declines 0.5% a year. The business is worth about $21.2 billion, debt is about $6.9 billion, leaving about $14.4 billion for shareholders. Debt. Total debt is about $7.26 billion at face value (notes of $7.02 billion and finance leases of $240 million) plus $34 million of short-term borrowings, less $218 million of cash, plus $43 million still to be paid in the first quarter of fiscal 2027 under settlements of cooking spray product liability claims, giving net debt of about $7.12 billion. Notes average a coupon of about 5.0%, below our 6% rate, so in the base and bull cases we reduce the debt by about $245 million. Maturities that matter: $762.5 million due October 2026, $1.0 billion of 1.375% notes due November 2027 (a very cheap coupon that will be replaced at a higher rate), and about $1.7 billion due in October and November 2028. What we left out. We do not credit any benefit from GLP-1 weight-loss drugs, although management says its portion-controlled and high-protein products are well placed; the effect on sales is not yet visible. We assume no acquisitions, margin recovery, buybacks or improvement in market sentiment. What we tested. We checked whether the profit decline was simply lost volume: underlying sales were roughly flat, so the damage is mainly cost inflation against limited pricing, which is why we assume it continues into fiscal 2027 rather than reversing. Cooking spray litigation is largely settled, with $141 million paid in fiscal 2026 and a $22.9 million judgment in the Esparza case under appeal; a few unsettled claims remain, and adverse outcomes would reduce all three cases modestly. Change since our earlier analysis. We previously estimated $5.04, $15.88 and $28.37 (bear, base, bull). The base and bear are lower and the bull higher. We now value the business before its lenders at a flat 6% rate and deduct the debt, start from fiscal 2026 results rather than adding back write-downs to reach a higher normal level, and reflect the planned fiscal 2027 capital spending step-up. What would prove us wrong: if input costs ease and volumes stabilize, business cash flow could return toward $3 per share, worth well above our base; if inflation persists and refinancing gets costly, the bear case applies.